Nektar Therapeutics dropped 8.6% despite raising substantial capital and reporting positive clinical data. The biotech company completed two equity offerings…
Read More

Nektar Therapeutics dropped 8.6% despite raising substantial capital and reporting positive clinical data. The biotech company completed two equity offerings…
Read More
Nektar Therapeutics recently completed a follow-on equity offering of about US$325.00 million and later closed an underwritten public offering totaling…
Read More
Global pharma powerhoutilize Eli Lilly and Incyte have announced a major regulatory milestone today: the European Medicines Agency’s (EMA) Committee…
Read More